FDA Approves New MRI Contrast
Bayer's AMBELVIST® (gadoquatrane) Receives FDA Approval for Enhanced MRI Imaging
Anonymous
The U.S. Food and Drug Administration approved Bayer's AMBELVIST® (gadoquatrane) on June 15, 2026, making it the first high-relaxivity macrocyclic gadolinium-based contrast agent cleared for MRI use in the United States. Business Wire reported the drug works in both adults and children aged 2 and older, detecting lesions with abnormal vascularity in the brain, spine, and other body regions.
The approval is a strategic milestone for Bayer. AMBELVIST® delivers the same diagnostic power as older agents at half the gadolinium dose — 0.05 mmol/kg versus the standard 0.1 mmol/kg. Stefan Oelrich, a Board member at Bayer AG, said the drug ensures "physicians don't have to choose between diagnostic confidence and patient safety."
Half the Gadolinium, Same Diagnostic Power
AMBELVIST® is a tetrameric macrocyclic agent. That means it is chemically more stable than older "linear" agents and holds onto gadolinium more tightly inside the body. Its higher "relaxivity" — the ability to brighten MRI images — allows doctors to use far less of the metal without losing image quality. Phase III trials covering over 1,500 patients across 20 countries showed a 98.2% non-inferiority rate compared to the leading rival drug, gadobutrol, at full dose, according to Barchart.
The trials, called QUANTI and QUANTE, began in September 2022. Bayer submitted its New Drug Application to the FDA in September 2025. The FDA granted Priority Review in January 2026, citing the drug's potential to reduce gadolinium retention in patients. Dr. Lawrence Tanenbaum, a neuroradiologist involved in the trials, called the result "a paradigm shift for the industry."
Gadolinium Safety Fears Drove a Decade of Research
The push for a lower-dose agent traces back to 2017, when the FDA warned that gadolinium from older MRI contrast agents was staying inside the brain and body. Those older "linear" agents were less stable and more likely to release free gadolinium ions. Macrocyclic agents like AMBELVIST® are much more tightly bound, making them harder for the body to break apart, according to MarketScreener.
Bayer itself faced thousands of lawsuits in the late 2010s linked to Nephrogenic Systemic Fibrosis and gadolinium deposition disease from its older products. AMBELVIST® is widely seen as a way to replace those agents and reduce long-term legal risk. A 2025 pre-print in JAMA Radiology did raise a flag, noting that even low-dose macrocyclics leave traces in bone — though researchers said the health impact is still unknown.
Bayer Bets on $800M Peak Sales Before Gadavist Patents Erode
Bayer expects AMBELVIST® to reach peak annual sales of $600 million to $800 million by 2030. The drug will likely carry a 20–30% price premium over generic macrocyclic agents. JP Morgan analyst Richard Vosser said Bayer is "effectively resetting the gold standard for contrast before Gadavist faces heavy patent erosion," noting the new drug will likely eat into sales of Bayer's older flagship, Gadavist, according to Barchart.
Bayer currently holds about 25% of the global contrast media market, valued at $2.5 billion. Analysts expect that share to climb toward 30% by 2028. Rivals Guerbet and GE HealthCare pushed back, calling the approval "incremental" and pointing out that their existing drugs have decades of safety data that AMBELVIST® does not yet have.
Doctors and Patient Groups Offer Cautious Welcome
The American College of Radiology issued a statement welcoming the approval, especially for pediatric patients and people who need repeated MRI scans — such as those with Multiple Sclerosis — where cumulative gadolinium exposure is a real concern. Hospitals will need to update imaging protocols and recalibrate automated injection systems to handle the new half-dose standard, according to Markets Financial Content.
Patient advocacy groups offered a more guarded response. The Gadolinium Toxicity Outreach Group said "lower dose is better, but zero dose is the ultimate goal." The FDA approval may also prompt regulators to reassess the safety limits of older linear agents still used in liver imaging, potentially pushing them toward phase-out in coming years.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
6
Articles
6
Reach
6
Topics
A
AnonymousAuthor
